The study will evaluate ReActiv8 compared to a patient’s optimal medical management, according to a news release. ReActiv8 is designed to help patients with intractable chronic low back pain.
The trial will be done at 25 centers in the U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.